Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC)

Authors :: Sergio J Azevedo
Geraldo Felicio Cunha
Andrew M. Scott
Venancio Avancini Ferreira Alves
Eric W. Hoffman
J. Sabbaga
Oren Smaletz
Ana Maria Moro
R. L. Costa
Claudio Calazan do Carmo
Carlos Barrios
M. D. P. Diz
Fernando Cotait Maluf
Ana Gabriela M. Fontana
L. J. Old
Source :: Journal of Clinical Oncology. 29:5078-5078
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 5078 Background: Lewis-Y (LeY) antigen is a blood group related antigen expressed in 75% of OC. hu3S193 is a humanized anti-LeY IgG1 mAb with strong complement dependent cytotoxicity and excellent ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Peritoneal cancer
medicine.drug_class
business.industry
medicine.disease
Monoclonal antibody
Complement-dependent cytotoxicity
Antigen
Refractory
Fallopian tube cancer
Internal medicine
medicine
Cancer research
Ovarian cancer
business
Platinum resistant

Tools